696 / 1068
RAPIDO-Trial
(randomized phase III)
MRI-defined high-risk criteria:
cT4 or MRF+ or N2 or lateral N+ or EMVI+
RT 50.4 Gy +
Capecitabine
825 mg/m
2
bid
(Optional)
CAPOX
8#, q21
T
M
E
Wk 14-16
R
5 x 5
Gy
CAPOX
6#, q21
T
M
E
Wk 22-24
Primary endpoint: 3y-DFS (50% > 60%), 885 pts. required